Long-term outcome of children receiving antiretroviral treatment in rural South Africa: Substantial virologic failure on first-line treatment

Pediatric Infectious Disease Journal

Volumn 30, Issue 1, 2011, Pages 52-56

  Barth, Roos E ^a   Tempelman, Hugo A ^b   Smelt, Elbert ^a   Wensing, Annemarie M J ^a   Hoepelman, Andy I ^a   Geelen, Sibyl P ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Ndlovu Medical Centre   (South Africa)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Africa; antiretroviral therapy; child; HIV; virologic failure

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RURAL AREA; SCHOOL CHILD; SOUTH AFRICA;

EID: 78650775221     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181ed2af3     Document Type: Article

References (37)

1. World Health Organization. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. Available at: http://www.who.int/hiv/pub/towards-universal-access-report-2008.pdf. Accessed May 2010.
2. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364:1236-1243.
3. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008;8:477-489.
4. Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009;49:1915-1927.
5. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach 2006. Available at: http://www.who.int/hiv/pub/ guidelines/art/en/. Accessed May 2010.
6. World Health Organization. WHO child growth standards. 2007. Available at: http://www.who.int/childgrowth/standards/weight-for-length/en/index.html and http://www.who.int/growthref/en/. Accessed November 1, 2009.
7. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2009:1-139. Available at: http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf. Accessed May 2010.
8. Los Alamos National Laboratory. HIV sequence database. 2005-2006. Available at: http://www.hiv.lanl.gov/content/sequence/SUDI/sudi.html.
9. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med. 2008;16:62-68.
10. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899.
11. Davies MA, Boulle A, Fakir T, et al. Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr. 2008; 8:34.
12. Arpadi SM. Growth failure in children with HIV infection. J Acquir Immune Defic Syndr. 2000;25(suppl 1):S37-S42.
13. Kekitiinwa A, Lee KJ, Walker AS, et al. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr. 2008;49:384-392.
14. Kabue MM, Kekitiinwa A, Maganda A, et al. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDS. 2008;22:245-251.
15. Bock P, Boulle A, White C, et al. Provision of antiretroviral therapy to children within the public sector of South Africa. Trans R Soc Trop Med Hyg. 2008;102:905-911.
16. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18: 1905-1913.
17. Song R, Jelagat J, Dzombo D, et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics. 2007;120:e856-e861.
18. Van Griensven J, De Naeyer L, Uwera J, et al. Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/ nurse-based care. BMC Pediatr. 2008;8:39.
19. Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20:2315-2319.
20. Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ. 2008;86:678-687.
21. Jaspan HB, Berrisford AE, Boulle AM. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J. 2008;27:993-998.
22. Muller AD, Myer L, Jaspan H. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy. Clin Infect Dis. 2009;48:e3-e5.
23. Adje-Toure C, Hanson DL, Talla-Nzussouo N, et al. Virologic and immu-nologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses. 2008;24:911-917.
24. Chaix ML, Rouet F, Kouakoussui KA, et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cote d'Ivoire. Pediatr Infect Dis J. 2005;24:1072-1076.
25. Gody JC, Charpentier C, Mbitikon O, et al. High prevalence of antiretro-viral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. J Acquir Immune Defic Syndr. 2008;49:566-569.
26. Lwembe R, Ochieng W, Panikulam A, et al. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol. 2007;79:865-872.
27. Pillay V, Pillay C, Kantor R, et al. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1449-1454.
28. Germanaud D, Derache A, Traore M, et al. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcrip-tase inhibitor first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother. 2010;65:118-124.
29. Barth RE, Wensing AM, Tempelman HA, et al. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS. 2008;22:2210-2212.
30. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-147.
31. Musiime V, Ssali F, Kayiwa J, et al. Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine. AIDS Res Hum Retroviruses. 2009; 25:989-996.
32. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409-417.
33. De Baets AJ, Ramet J, Msellati P, et al. The unique features of pediatric HIV-1 in sub-Saharan Africa. Curr HIV Res. 2008;6:351-362.
34. Gibb DM, Goodall RL, Giacomet V, et al. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J. 2003;22:56-62. (Pubitemid 36091779)
35. Muller AD, Bode S, Myer L, et al. Electronic measurement of adherence to pediatric antiretroviral therapy in South Africa. Pediatr Infect Dis J. 2008;27:257-262.
36. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiret-roviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009;49:454-462.
37. Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22:1971-1977.